Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumors - CPT-PED-05

CPT-PED-05 administrative office0 个研究点目标入组 30 人开始时间: 2006年1月27日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) a patient who received transfusion, blood products, or hematopoietic growth factors such as G-CSF within 7 days prior to the registration 2) a patient who has another active malignant disease, which is untreated or whose control period is less than 5years, in different site 3) a patient with symptomatic metastasis to central nervous system, or a patient with primary central nervous system tumor 4) a patient who is complicated with serious disease as below; 1. infection, diarrhea, ileus, paralytic ileus 2. malignant fluid retention (pleural effusion, ascites, pericardiac effusion) 3. interstitial pneumonia or pulmonary fibrosis 4. cardiac disease 5. other disease which possibly interfere the trial 5) a patient who is pregnant, during breast-feeding, possibly pregnant, or willing to be pregnant 6) past history of serious drug allergy 7) past history of administration of CPT-11 8) a patient who was judged as inappropriate for the trial

发起方

CPT-PED-05 administrative office